TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11907291

Group type: EXPERIMENTAL
Intervention: Inpatient geriatric unit care
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Outpatient geriatric clinic care
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 1388
Study: 9463741

Group type: EXPERIMENTAL
Intervention: Home blood glucose monitors (17 devices: 2 visually read, 8 colorimetric, 7 amperometric)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dedicated glucose analyser
Number of subjects: 50
Study: 8556900

Group type: EXPERIMENTAL
Intervention: Skill-based training program to enhance maternal sensitivity between 6 and 9 months of age
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Skill-based training program to enhance maternal sensitivity
Number of subjects: 82
Study: 1977330

Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg) and Vecuronium (0.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg) and Atracurium (1.0 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg) and Vecuronium (0.2 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 micrograms/kg) and Atracurium (1.0 mg/kg)
Number of subjects: 0
Study: 500517

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate in non-fasting subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin base
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin base
Number of subjects: 0
Study: 31862277

Group type: EXPERIMENTAL
Intervention: Jacobson's relaxation technique (20‐30min daily for three consecutive days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care and treatment (control group)
Number of subjects: 80
Study: 30087153

Group type: EXPERIMENTAL
Intervention: 10 mL/kg fluid bolus every 15 min for up to 4 hours
Number of subjects: 75

Group type: COMPARATOR
Intervention: 20 mL/kg fluid bolus every 15 min for up to 4 hours
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study: 27522514

Group type: EXPERIMENTAL
Intervention: Invasive blood pressure monitoring
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-invasive blood pressure monitoring
Number of subjects: 58
Study: 25741969

Group type: COMPARATOR
Intervention: Short-course ARV (antenatal zidovudine with single-dose nevirapine)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Triple ARV prophylaxis until breastfeeding cessation
Number of subjects: 753
Study: 23506731

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg) daily
Number of subjects: 197
Study: 21254985

Group type: EXPERIMENTAL
Intervention: Underbody forced-air warming
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Underbody resistive heating mattress
Number of subjects: 129

Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 129
Study: 20021912

Group type: EXPERIMENTAL
Intervention: 0.15 U/(kg.d) growth hormone (Somatropin, S19990021) in A(1) and B(1) groups
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 0.2 U/(kg.d) growth hormone in A(2) and B(2) groups
Number of subjects: 210

Group type: COMPARATOR
Intervention: No growth hormone (NS) in A(0) and B(0) groups
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 0.15 U/(kg.d) growth hormone in A(1) and B(1) groups
Number of subjects: 210
Study: 16703541

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1% (Ophthalin)
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2% hydroxypropyl methylcellulose (HPMC-Ophtal)
Number of subjects: 110
Study: 14628282

Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 134

Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 134
Study: 11127254

Group type: EXPERIMENTAL
Intervention: DEC-medicated salt (0.33% w/w) for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: DEC-medicated salt (0.33% w/w)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal cooking salt (control)
Number of subjects: 40
Study: 9120921

Group type: EXPERIMENTAL
Intervention: Fat injections
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Collagen injections
Number of subjects: 67
Study: 8443252

Group type: EXPERIMENTAL
Intervention: 8-week educational and walking program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Weekly telephone survey
Number of subjects: 102
Study: 3537462

Group type: EXPERIMENTAL
Intervention: Peritoneovenous shunt (N = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medical Therapy (N = 10)
Number of subjects: 20
Study: 31739753

Group type: EXPERIMENTAL
Intervention: Practice condition (10 sessions of Stroop Test)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control condition (pretest and posttest only)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Practice condition (older adults with higher educational level)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Practice condition (older adults)
Number of subjects: 93
Study: 31419322

Group type: EXPERIMENTAL
Intervention: DTPw (cellular Bordetella pertussis vaccine)
Number of subjects: 265

Group type: COMPARATOR
Intervention: DTPa (acellular Bordetella pertussis vaccine)
Number of subjects: 265
Study: 29016822

Group type: EXPERIMENTAL
Intervention: Bupropion-Plus-Escitalopram
Number of subjects: 166

Group type: COMPARATOR
Intervention: Escitalopram-Plus-Placebo
Number of subjects: 166

Group type: COMPARATOR
Intervention: Venlafaxine-Plus-Mirtazapine
Number of subjects: 166
Study: 26409158

Group type: EXPERIMENTAL
Intervention: Acceptance & Commitment Therapy (ACT)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Expressive Writing (Control)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 238
Study: 24019539

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: BRAF(V600E) mutations
Number of subjects: 2686

Group type: EXPERIMENTAL
Intervention: KRAS mutations
Number of subjects: 2686
Study: 21300246

Group type: EXPERIMENTAL
Intervention: Inadequate pretreatment oral hygiene
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Diseased first molars
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Presence of WSLs
Number of subjects: 230
Study: 19741484

Group type: EXPERIMENTAL
Intervention: Propofol (0-12 microg/ml) and Sevoflurane (0-3.5 vol.%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol (0-12 microg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0-3.5 vol.%)
Number of subjects: 60
Study: 17012720

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 15
Study: 15104193

Group type: EXPERIMENTAL
Intervention: Integrated pest management intervention (filling holes with copper mesh, vacuuming and cleaning, using low-toxicity pesticides and traps)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control homes (no intervention)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Integrated pest management intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 18
Study: 11352440

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg administered orally after 250g of yoghurt
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moxifloxacin 400mg administered orally under fasting conditions
Number of subjects: 12
Study: 9499661

Group type: EXPERIMENTAL
Intervention: Motile neutrophils
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motile monocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Resting neutrophils and monocytes
Number of subjects: 0
Study: 8200006

Group type: EXPERIMENTAL
Intervention: Single high dose dactinomycin (60 mcg/kg x 1 day)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard fractionated dactinomycin (15 mcg/kg x 5 days)
Number of subjects: 176
Study: 2965631

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 0.4 pmol min-1 kg-1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 2 pmol min-1 kg-1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 10 pmol min-1 kg-1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 6
Study: 29677572

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 173
Study: 28860599

Group type: EXPERIMENTAL
Intervention: Risk prediction model for ESRD
Number of subjects: 24104
Study: 26138018

Group type: EXPERIMENTAL
Intervention: Duke Anticoagulation Satisfaction Scale (DASS)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-12)
Number of subjects: 326

Group type: COMPARATOR
Intervention: INR control
Number of subjects: 326
Study: 24640666

Group type: EXPERIMENTAL
Intervention: levofloxacin (Glevo) 500 mg/day
Number of subjects: 147

Group type: COMPARATOR
Intervention: original levofloxacin 500 mg/day
Number of subjects: 147

Group type: COMPARATOR
Intervention: standard therapy
Number of subjects: 147
Study: 21671419

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach
Number of subjects: 701

Group type: COMPARATOR
Intervention: Control group (active management advice)
Number of subjects: 701
Study: 19178516

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 20 mg every 28 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 104
Study: 17162624

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/d)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 15538079

Group type: EXPERIMENTAL
Intervention: Oral antioxidants (oxygenated carotenoid - lutein)
Number of subjects: 50
Study: 11524488

Group type: EXPERIMENTAL
Intervention: Vascular cognitive impairment without dementia (CIND)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Women with vascular cognitive impairment without dementia (CIND)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Participants alive without dementia after 5 years
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall cohort of vascular CIND
Number of subjects: 149
Study: 9642972

Group type: EXPERIMENTAL
Intervention: Clonazepam (1.5 to 3 mg daily)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (non-akathitic schizophrenic patients)
Number of subjects: 4
Study: 8495680

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 0.005% alfentanil (n = 31)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.25% bupivacaine (n = 29)
Number of subjects: 70
Study: 2954800

Group type: EXPERIMENTAL
Intervention: Pure porcine insulin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Partially purified bovine/porcine insulin
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 28870743

Group type: EXPERIMENTAL
Intervention: CT-based 2D-3D matched navigation group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paired-point matched navigation group (PPM)
Number of subjects: 80
Study: 26645257

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) plus rehabilitation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 21
Study: 24157530

Group type: EXPERIMENTAL
Intervention: Living at 2,085 m
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Living at 2,454 m
Number of subjects: 48

Group type: COMPARATOR
Intervention: Living at 1,780 m
Number of subjects: 48

Group type: COMPARATOR
Intervention: Living at 2,800 m
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study: 23902631

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation to the ventral striatum/anterior limb of the internal capsule
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation
Number of subjects: 10
Study: 20570290

Group type: EXPERIMENTAL
Intervention: Cefazolin continuous infusion (1 g every 6 hours for 18 hours after an initial 2 g dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefazolin intermittent administration (1 g at 3, 9, and 15 hours after an initial 2 g dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefazolin continuous infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefazolin intermittent administration
Number of subjects: 20
Study: 18990202

Group type: EXPERIMENTAL
Intervention: Oxford Handicap Scale (OHS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OHS dichotomy separating patients with severe dependency or death
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OHS among survivors at hospital discharge
Number of subjects: 0
Study: 21350689

Group type: EXPERIMENTAL
Intervention: OVD
Number of subjects: 62

Group type: COMPARATOR
Intervention: BSS
Number of subjects: 62
Study: 16135930

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 247

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 247
Study: 12124550

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg orally every 8 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no steroids or NSAIDs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diclofenac-treated group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 9585797

Group type: EXPERIMENTAL
Intervention: 80 mg/day ipsapirone CR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg/day fluoxetine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7635364

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with 0.5 ml of inseminate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fallopian sperm perfusion (FSP) with 4 ml of inseminate
Number of subjects: 60
Study: 2712130

Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 46

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 46
Study: 408844

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-amphetamine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11161899

Group type: EXPERIMENTAL
Intervention: ESBL-KP
Number of subjects: 92

Group type: COMPARATOR
Intervention: non-ESBL-KP
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Carbapenems
Number of subjects: 92
Study: 31013226

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for up to 5 days before surgery)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Medication-free group (no aspirin)
Number of subjects: 572
Study: 30158152

Group type: EXPERIMENTAL
Intervention: Tenapanor (15 mg, given twice daily for 4 days)
Number of subjects: 0
Study: 27623732

Group type: EXPERIMENTAL
Intervention: All-inside arthroscopic MBO
Number of subjects: 48

Group type: COMPARATOR
Intervention: Open MBO
Number of subjects: 48
Study: 24569916

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin‐based combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystectomy alone or surgery followed by adjuvant chemotherapy
Number of subjects: 0
Study: 23230999

Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg under fed conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Doxylamine hydrogen succinate 25 mg under fasting conditions
Number of subjects: 24
Study: 20500493

Group type: EXPERIMENTAL
Intervention: Immediate everolimus (IE)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Delayed everolimus (DE)
Number of subjects: 139
Study: 17610347

Group type: EXPERIMENTAL
Intervention: Enoxaparin-based regimen
Number of subjects: 2

Group type: COMPARATOR
Intervention: UFH/PPC-based regimen
Number of subjects: 2
Study: 15850130

Group type: EXPERIMENTAL
Intervention: Complex Demodulation (CDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Power Spectral Analysis (PSA)
Number of subjects: 0
Study: 12850621

Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar vessel sealer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 60
Study: 10568115

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (Duraflo II, n = 20)
Number of subjects: 40
Study: 8911631

Group type: EXPERIMENTAL
Intervention: IVIG infusions (200-250 mg/kg) every 3 weeks during the first 8 months of pregnancy
Number of subjects: 35
Study: 1868270

Group type: EXPERIMENTAL
Intervention: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle, followed by no other therapy (Group 1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Synthetic hPTH (1‐38) for the first 14 days of a 100 day cycle followed by salmon calcitonin at an average dose of 79 units per day for a 56 day depressor period (Group 2)
Number of subjects: 2
Study: 7040782

Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nondopamine group (Control)
Number of subjects: 50
Study: 31711671

Group type: EXPERIMENTAL
Intervention: Digoxin administered intraamniotically or intrafetally prior to second-trimester surgical abortion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 0
Study: 29863842

Group type: EXPERIMENTAL
Intervention: Onion-ring-like g-C3N4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bulk g-C3N4
Number of subjects: 0
Study: 26360921

Group type: EXPERIMENTAL
Intervention: Continuous flow limb hypothermia at coolant temperatures between 25 °C and 20 °C for three hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuous flow limb hypothermia at coolant temperatures as low as 22 °C
Number of subjects: 15
Study: 24047244

Group type: EXPERIMENTAL
Intervention: Foot Massage (FM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control Activity (Quiet Presence, QP)
Number of subjects: 53
Study: 23534333

Group type: EXPERIMENTAL
Intervention: RPE treatment (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated controls (n = 11)
Number of subjects: 23
Study: 21034619

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 17437965

Group type: EXPERIMENTAL
Intervention: Cinitapride (CTP; 1 mg t.i.d.) + ketoconazole (KET; 200 mg b.i.d.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cinitapride (CTP; 1 mg t.i.d.) + placebo (PL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL) + ketoconazole (KET; 200 mg b.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL) + placebo (PL)
Number of subjects: 16
Study: 17902397

Group type: EXPERIMENTAL
Intervention: Training in the meaning of the symbols
Number of subjects: 2

Group type: COMPARATOR
Intervention: No training
Number of subjects: 2
Study: 12196473

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 10461824

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg
Number of subjects: 0
Study: 7835575

Group type: EXPERIMENTAL
Intervention: Mesalamine (3 g/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 2151276

Group type: EXPERIMENTAL
Intervention: Zoladex plus flutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoladex plus placebo
Number of subjects: 0
Study: 385260

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31818058

Group type: EXPERIMENTAL
Intervention: Music (M)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No Music (NM)
Number of subjects: 15
Study: 31129719

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28124127

Group type: EXPERIMENTAL
Intervention: Endurance exercise (END: 30 min cycling, 70% VO2peak)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX: 4 × 10 leg press repetitions, 70% 1-RM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-intensity cycling with blood-flow restriction (BFR: 15 min, 40% VO2peak)
Number of subjects: 9
Study: 25919835

Group type: EXPERIMENTAL
Intervention: Increase to 30 mg/d of mirtazapine (increase(30) group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Maintain at 15 mg/d of mirtazapine (stay(15) group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increase to 45 mg/d of mirtazapine (increase(45) group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Maintain at 30 mg/d of mirtazapine (stay(30) group)
Number of subjects: 44
Study: 24919430

Group type: EXPERIMENTAL
Intervention: Web-based GA-coping computer game
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-medical game
Number of subjects: 210
Study: 22961272

Group type: EXPERIMENTAL
Intervention: Local injections of rhGH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 19773751

Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant chemotherapy
Number of subjects: 409

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: High EZH2 expression
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: High proliferation (>or=40%)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Randomisation group (high proliferation)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Stage III
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: High histological grade
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: High proliferation
Number of subjects: 409
Study: 17706059

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration salts (ROORS)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Oral rehydration salts II (ORS II)
Number of subjects: 125
Study: 15045139

Group type: EXPERIMENTAL
Intervention: IGIV-C (1 g/kg/day for 2 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: IGIV-S/D (1 g/kg/day for 2 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 97

Group type: COMPARATOR
Intervention: IGIV-S/D
Number of subjects: 97